Achieve Life Sciences
NASDAQ: ACHVVancouver, B.C., US · Delaware corporation · 3 known investors
Find your way into Achieve Life Sciences
633 people in our graph share verified history with the Achieve Life Sciences team — schools, employers, funds. One of them is your warm intro.
Paul Bragielunlockedknows Jaime Xinos · together at University of Illinois Urbana-Champaign (overlapped)
%20(1).png)
×4knows the team · via University of Illinois Urbana-Champaign
knows the team · via The George Washington University
knows the team · via Achieve Life Sciences
×3knows the team · via University of San Diego
knows the team · via University of Washington - School of Medicine
Achieve Life Sciences is a late-stage specialty pharmaceutical company developing cytisinicline, a treatment for nicotine dependence and smoking cessation. It is pursuing FDA approval for the drug as a new option for people trying to quit smoking or vaping in the US.
Founders & leadership
AC
Anthony ClarkeCo-founder
RS
Richard StewartCo-founder
CJ
Cindy JacobsinPresident, Chief Medical Officer and Past Board Director2017–2025Dr. Jacobs is a pharmaceutical executive with over 30 years in drug development and regulatory affairs, including leadership roles in clinical development, acquisitions, and joint ventures with major pharmaceutical companies; she served as President and Chief Medical Officer of Achieve Life Sciences from 2017 to 2025, where she focused on advancing regulatory approvals for cytisinicline in smoking cessation, and currently runs an executive consulting firm advising on C-suite leadership and pharmaceutical strategy.
JX
Jaime XinosinChief Commercial Officer (CCO)2024–2026Jaime Xinos is Executive Officer at Achieve Life Sciences and brings 26 years of pharmaceutical and biotechnology experience from roles including Chief Commercial Officer at Achieve Life Sciences, Chief Commercial Officer roles at major companies including Abbott, Novartis, and Pfizer, with expertise in commercial strategy and product launches across oncology and specialty markets.
JB
John BencichinChief Executive Officer, Member of the Board of Directors2020–2024John Bencich is an executive officer and director at Achieve Life Sciences, a late-stage specialty pharmaceutical company developing cytisinicline for smoking cessation. He brings 25 years of experience in life sciences and biotechnology, with expertise in corporate strategy, financial leadership, capital raising, and M&A across companies ranging from early-stage ventures to NASDAQ-listed firms.
AD
Andrew D. GoldberginCEO & Board Director
Board
Investors · 3
Reported raises · per SEC filings
Form D private placements$18.9M disclosed across 1 round · 2022
▶$18.9MraisedDec 2022 · 16 investors · BiotechnologyRule 506(b)
▶$18.9MraisedDec 2022 · 16 investors · Biotechnology
Rule 506(b)Officers, directors & promoters on the filing
- Cindy JacobsExecutive Officer, Director
- Anthony ClarkeExecutive Officer
- Bridget MartellDirector
- Martin MattinglyDirector
- Jaime XinosExecutive Officer
- Vaughn HimesDirector
- Donald JosephDirector
- John BencichExecutive Officer, Director
- Richard StewartDirector
- Jay MoyesDirector
- Offering amount
- $25M
- Amount sold
- $18.9M
- Finders' fees
- $756K
- First sale
- Nov 2022
- Incorporated
- Corporation, Delaware
- Federal exemptions
- 06b
Source: SEC EDGAR Form D. Amounts as filed; amended filings shown once at their latest values.
Competitors · 1
by search overlap
Companies competing with Achieve Life Sciences for the same Google search keywords, organic and paid, via search-intersection analysis.
Non-dilutive funding · 2 SBIR/STTR awards
Federal grants — no equity taken| Agency | Phase | Year | Amount |
|---|---|---|---|
| National Institutes of Health (NIH)National Institutes of Health | Phase II | 2022 | $2.5M |
| National Institutes of Health (NIH)National Institutes of Health | Phase ISTTR | 2021 | $320K |
Source: SBIR.gov award data (U.S. Small Business Administration). SBIR/STTR awards are competitive federal R&D grants and contracts — non-dilutive capital alongside any venture rounds above.
In the news
Achieve Life Sciences (NASDAQ: ACHV) posts larger Q2 2026 loss but secures $354M financingstocktitan.net · Aug 2026Frequently asked questions
- What does Achieve Life Sciences do?
- Achieve Life Sciences is a late-stage specialty pharmaceutical company developing cytisinicline, a treatment for nicotine dependence and smoking cessation. It is pursuing FDA approval for the drug as a new option for people trying to quit smoking or vaping in the US.
- Who founded Achieve Life Sciences?
- Achieve Life Sciences was founded by Anthony Clarke, Richard Stewart.
- Who are Achieve Life Sciences's investors?
- Achieve Life Sciences's investors include venBio Partners, Vivo Capital, Frazier Life Sciences.
- How much funding has Achieve Life Sciences raised?
- Achieve Life Sciences has disclosed $18.9M raised across 1 round.
- Where is Achieve Life Sciences headquartered?
- Achieve Life Sciences is headquartered in Vancouver, B.C., US.